Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals

April 1, 2015

Salix Pharmaceuticals is a specialty pharmaceutical company that offers innovative gastroenterology treatments.

PRESS RELEASE

LAVAL, Quebec

,

April 1, 2015

/PRNewswire/ --

Valeant Pharmaceuticals International, Inc.

(NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of

Salix Pharmaceuticals, Ltd.

Salix Pharmaceuticals

is a specialty pharmaceutical company that offers innovative gastroenterology treatments such as XIFAXAN® (rifaximin) 550 mg, RUCONEST® (C1 esterase inhibitor [recombinant]), APRISO® (mesalamine), UCERIS® (budesonide) extended release tablets and RELISTOR® (methylnaltrexone bromide).

About

Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc.

(NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about

Valeant Pharmaceuticals International, Inc.

can be found at www.valeant.com.